Effect of selected NAD+ analogues on mitochondria activity and proliferation of endothelial EA.hy926 cells

European Journal of Pharmacology

Volumn 640, Issue 1-3, 2010, Pages 102-111

  Nowak, Robert ^a   Wrzosek, Antoni ^b   Łukasiak, Agnieszka ^b,c   Rutkowska, Magdalena ^a   Adamus, Jan ^d   Geogonekbicki, Jerzy ^d   Dołowy, Krzysztof ^c   Szewczyk, Adam ^b   Tarasiuk, Jolanta ^a  

^a UNIVERSITY OF SZCZECIN   (Poland)

^b NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

^c WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

^d LODZ UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

1 methylnicotinamide; Cell proliferation; Endothelial EA.hy926 cells; Mitochondria metabolism; NAD+ analogues; Nicotinamide

Indexed keywords

1 METHYL 3 NITROPYRIDINE; 1 METHYLNICOTINAMIDE; ADENOSINE TRIPHOSPHATE; CALCIUM ION; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; 1-METHYL-3-NITROPYRIDINIUM; CALCIUM; N(1)-METHYLNICOTINAMIDE; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; OXYGEN; PYRIDINIUM DERIVATIVE;

ARTICLE; CELL ACTIVITY; CELL CYCLE; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; CELL LINE; CHEMISTRY; CYTOLOGY; CYTOSOL; DRUG EFFECTS; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ADENOSINE TRIPHOSPHATE; BIOLOGICAL TRANSPORT; CALCIUM; CELL CYCLE; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CYTOSOL; ENDOTHELIAL CELLS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; NAD; NIACINAMIDE; OXYGEN; PYRIDINES; PYRIDINIUM COMPOUNDS;

EID: 77953806993     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.04.027     Document Type: Article

References (52)

1. Aon M.A., Cortassa S., O'Rourke B. Mitochondrial oscillations in physiology and pathophysiology. Adv. Exp. Med. Biol. 2008, 641:98-117.
2. Bartuś M., Łomnicka M., Kostogrys R.B., Kaźmierczak P., Watała C., Słominska E.M., Smoleński R.T., Pisulewski P.M., Adamus J., Gebicki J., Chlopicki S. 1-Methylnicotinamide (MNA) prevents endothelial dysfunction in hypertriglyceridemic and diabetic rats. Pharmacol. Rep. 2008, 60:127-138.
3. + metabolism in health and disease. Trends Biochem. Sci. 2007, 32:12-19.
4. Bernier J., Stratford M.R., Denekamp J., Dennis M.F., Bieri S., Hagen F., Kocagöncü O., Bolla M., Rojas A. Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer. Radiother. Oncol. 1998, 48:123-133.
5. Biedroń R., Ciszek M., Tokarczyk M., Bobek M., Kurnyta M., Słominska E.M., Smoleński R.T., Marcinkiewicz J. 1-Methylnicotinamide and nicotinamide: two related anti-inflammatory agents that differentially affect the functions of activated macrophages. Arch. Immunol. Ther. Exp. 2008, 56:127-134.
6. Bryniarski K., Biedron R., Jakubowski A., Chlopicki S., Marcinkiewicz J. Anti-inflammatory effect of 1-methylnicotinamide in contact hypersensitivity to oxazolone in mice; involvement of prostacyclin. Eur. J. Pharmacol. 2008, 578:332-338.
7. Bugs M.R., Bortoleto-Bugs R.K., Cornélio M.L. The interaction between heparin and Lys49 phospholipase A2 reveals the natural binding of heparin on the enzyme. Int. J. Biol. Macromol. 2005, 37:21-27.
8. Chaidemenus G.C. Tetracycline and niacinamide in the treatment of blistering skin diseases. Clin. Dermatol. 2001, 19:781-785.
9. Chlopicki S., Swies J., Mogielnicki A., Buczko W., Bartus M., Lomnicka M., Adamus J., Gebicki J. 1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway. Br. J. Pharmacol. 2007, 152:230-239.
10. Chong Z.Z., Lin S.H., Maiese K. Nicotinamide modulates mitochondrial membrane potential and cysteine protease activity during cerebral vascular endothelial cell injury. J. Vasc. Res. 2002, 39:131-147.
11. + precursor nicotinamide governs neuronal survival during oxidative stress through protein kinase B coupled to FOXO3a and mitochondrial membrane potential. J. Cereb. Blood Flow Metab. 2004, 24:728-743.
12. Dragun P., Makarewicz D., Wojcik L., Ziemka-Nalecz M., Slomka M., Zalewska T. Matrix metaloproteinases activity during the evolution of hypoxic-ischemic brain damage in the immature rat. The effect of 1-methylnicotinamide (MNA). J. Physiol. Pharmacol. 2008, 59:441-455.
13. Edgell C.J.S., McDonald C.C., Graham J.B. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc. Natl Acad. Sci. USA 1983, 80:3734-3737.
14. Fukushima T., Kaetsu A., Lim H., Moriyama M. Possible role of 1-methylnicotinamide in the pathogenesis of Parkinson's disease. Exp. Toxicol. Pathol. 2002, 53:469-473.
15. Ganji S.H., Qin S., Zhang L., Kamanna V.S., Kashyap M.L. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 2009, 202:68-75.
16. Gebicki, J., Sysa-Jedrzejowska, A., Adamus, J., 2000. Compositions for the treatment of skin diseases. European Patent Ep 1147086.
17. Gebicki J., Sysa-Jedrzejowska A., Adamus J., Wozniacka A., Rybak M., Zielonka J. 1-Methylnicotinamide: a potent anti-inflammatory agent of vitamin origin. Pol. J. Pharmacol. 2003, 55:109-112.
18. +. Acc. Chem. Res. 2004, 37:379-386.
19. Głaogonekb M., Lojek A., Wrzosek A., Dołowy K., Szewczyk A. Endothelial mitochondria as a possible target for potassium channel modulators. Pharmacol. Rep. 2006, 58:89-95.
20. Hassa P.O., Haenni S.S., Elser M., Hottiger M.O. Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going?. Microbiol. Mol. Biol. Rev. 2006, 70:789-829.
21. Jezek P., Hlavata L. Mitochondria in homeostasis of reactive oxygen species in cell, tissues, and organism. Int. J. Biochem. Cell Biol. 2005, 37:2478-2503.
22. Jonas W.B., Rapoza C.P., Blair W.F. The effect of niacinamide on osteoarthritis: a pilot study. Inflamm. Res. 1996, 45:330-334.
23. +, as a PARP inhibitor and by partial restoration of mitochondrial function. Pharmacology 2003, 69:150-157.
24. Kuykendall J.R., Cox R., Kinder D. 1-Methylnicotinamide stimulates cell growth and inhibits hemoglobin synthesis in differentiating murine erythroleukemia cells. Toxicol. In vitro 2007, 21:1656-1662.
25. Lemasters J.J., Qian T., He L., Kim J.S., Elmore S.P., Cascio W.E., Brenner D.A. Role of mitochondrial inner membrane permeabilization in necrotic cell death, apoptosis, and autophagy. Antioxid. Redox Signal. 2002, 4:769-781.
26. + precursor nicotinamide. Curr. Med. Chem. 2006, 13:883-895.
27. Lomonte B., Tarkowski A., Bagge U., Hanson L.A. Neutralization of the cytolytic and myotoxic activities of phospholipases A2 from Bothrops asper snake venom by glycosaminoglycans of the heparin/heparan sulfate family. Biochem. Pharmacol. 1994, 47:1509-1518.
28. Maiese K., Chong Z.Z. Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain. Trends Pharmacol. Sci. 2003, 24:228-232.
29. Maruszewska A., Kostrzewa-Nowak D., Adamus J., Czuprynska K., Maryniak D., Gebicki J., Tarasiuk J. The ability of selected pyridinium salts to increase the cytotoxic activity of vincristine but not doxorubicin towards sensitive and multidrug resistant promyelocytic leukaemia HL60 cells. J. Pharm. Pharmacol. 2008, 60:647-653.
30. Merhi-Soussi F., Dominguez Z., Macovschi O., Dubois M., Nemoz G., Lagarde M., Prigent A.F. Mechanisms involved in the stimulation of prostacyclin synthesis by human lymphocytes in human umbilical vein endothelial cells. Br. J. Pharmacol. 2003, 139:321-328.
31. Musfeld C., Biollaz J., Bélaz N., Kesselring U.W., Decosterd L.A. Validation of an HPLC method for the determination of urinary and plasma levels of N1-methylnicotinamide, an endogenous marker of renal cationic transport and plasma flow. J. Pharm. Biomed. Anal. 2001, 24:391-404.
32. Orrenius S. Mitochondrial regulation of apoptotic cell death. Toxicol. Lett. 2004, 149:19-23.
33. Quintero M., Colombo S.L., Godfrey A., Moncada S. Mitochondria as signaling organelles in the vascular endothelium. Proc. Natl Acad. Sci. USA 2006, 103:5379-5384.
34. Shalita A.R., Smith J.G., Parish L.C., Sofman M.S., Chalker D.K. Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. Int. J. Dermatol. 1995, 34:434-437.
35. Shaw E.N. Quaternary pyridinium compounds. Pyridine Its Derivatives 1961, 1-31. Interscience Publishers, New York. E. Klingsberg (Ed.).
36. Slominska E.M., Yuen A., Osman L., Gebicki J., Yacoub M.H., Smolenski R.T. Cytoprotective effects of nicotinamide derivatives in endothelial cells. Nucleosides Nucleotides Nucleic Acids 2008, 27:863-866.
37. Slomka M., Zieminska E., Lazarewicz J. Nicotinamide and 1-methylnicotinamide reduce homocysteine neurotoxicity in primary cultures of rat cerebellar granule cells. Acta Neurobiol. Exp. 2008, 68:1-9.
38. Slomka M., Zieminska E., Salinska E., Lazarewicz J. Neuroprotective effects of nicotinamide and 1-methylnicotinamide in acute excitotoxicity in vitro. Folia Neuropathol. 2008, 46:69-80.
39. Smolenski R.T., Lachno D.R., Ledingham S.J.M., Yacoub M.H. Determination of sixteen nucleotides, nucleosides and bases using highperformance liquid chromatography and its application to the study of purine metabolism in hearts for transplantation. J. Chromatogr. 1990, 527:414-420.
40. Somogyi A., Siebert D., Bochner F. Determination of endogenous concentrations of N1-methylnicotinamide in human plasma and urine by high-performance liquid chromatography. Anal. Biochem. 1990, 187:160-165.
41. Traaseth N., Elfering S., Solien J., Haynes V., Giulivi C. Role of calcium signaling in the activation of mitochondrial nitric oxide synthase and citric acid cycle. Biochim. Biophys. Acta 2004, 1658:64-71.
42. Tran Q.K., Ohashi K., Watanabe H. Calcium signalling in endothelial cells. Cardiovasc. Res. 2000, 48:13-22.
43. Ungerstedt J.S., Blomback M., Soderstrom T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin. Exp. Immunol. 2003, 131:48-52.
44. Wieczorkowska M., Zielonka J., Adamus J., Ciesielska E., Marcinek A., Szmigiero L., Gebicki J. 1-Methyl-3-nitropyridine: an efficient oxidant of NADH in non-enzymatic and enzyme-mediated processes. Free Radic. Res. 2003, 37:1157-1162.
45. Wieczorkowska M., Szajerski P., Michalski R., Adamus J., Marcinek A., Gebicki J., Ciesielska E., Szmigiero L., Lech-Marańda E., Szmigielska-Kapłon A., Robak T. Cytotoxic activity of the selected pyridinium salts against murine leukemia L1210. Pharmacol. Rep. 2007, 59:216-223.
46. Wozniacka A., Wieczorkowska M., Gebicki J., Sysa-Jedrzejowska A. Topical application of 1-methylnicotinamide in the treatment of rosacea: a pilot study. Clin. Exp. Dermatol. 2005, 30:632-635.
47. Wrzosek A., Lukasiak A., Gwozdz P., Malinska D., Kozlovski V.I., Szewczyk A., Chlopicki S., Dolowy K. Large-conductance K+ channel opener CGS7184 as a regulator of endothelial cell function. Eur. J. Pharmacol. 2009, 602:105-111.
48. Yan L., Otterness D.M., Weinshilboum R.M. Human nicotinamide N-methyltransferase pharmacogenetics: gene sequence analysis and promoter characterization. Pharmacogenetics 1999, 9:307-316.
49. + levels dictate cell survival. Cell 2007, 130:1095-1107.
50. Yelamos J., Schreiber V., Dantzer F. Toward specific functions of poly(ADP-ribose) polymerase-2. Trends Mol. Med. 2008, 14:169-178.
51. +/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid. Redox Signal. 2008, 10:179-206.
52. Zhou S.S., Li D., Sun W.P., Guo M., Lun Y.Z., Zhou Y.M., Xiao F.C., Jing L.X., Sun S.X., Zhang L.B., Luo N., Bian F.N., Zou W., Dong L.B., Zhao Z.G., Li S.F., Gong X.J., Yu Z.G., Sun C.B., Zheng C.L., Jiang D.J., Li Z.N. Nicotinamide overload may play a role in the development of type 2 diabetes. World J. Gastroenterol. 2009, 15:5674-5684.